Effectiveness and safety of laropiprant on niacin-induced flushing

American Journal of Cardiology

Volumn 110, Issue 6, 2012, Pages 817-822

  MacCubbin, Darbie L ^a   Chen, Fabian ^a   Anderson, Jennifer Weimer ^a   Sirah, Waheeda ^a   McCrary Sisk, Christine ^a   Kher, Uma ^a   Olsson, Anders G ^b   Bays, Harold E ^c   Mitchel, Yale B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Stockholm Heart Center   (Sweden)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAROPIPRANT; NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ERYTHEMA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIACIN INDUCED FLUSHING; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FLUSHING; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865447632     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.05.009     Document Type: Article

References (9)

1. R.H. Knopp, J. Ginsberg, J.J. Albers, C. Hoff, J.T. Ogilvie, G.R. Warnick, E. Burrows, B. Retzlaff, M. Poole Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin Metabolism 34 1985 642 650
2. R.S. Birjmohun, B.A. Hutten, J.J. Kastelein, E.S. Stroes Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice Neth J Med 62 2004 229 234
3. D.R. Illingworth, E.A. Stein, Y.B. Mitchel, C.A. Dujovne, P.H. Frost, R.H. Knopp, P. Tun, R.V. Zupkis, R.A. Greguski Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial Arch Intern Med 154 1994 1586 1595
4. E. Mills, J. Prousky, G. Raskin, J. Gagnier, B. Rachlis, V.M. Montori, D. Juurlink The safety of over-the-counter niacin A randomized placebo-controlled trial [ISRCTN18054903] BMC Clin Pharmacol 3 2003 4 11
5. K. Cheng, T.J. Wu, K.K. Wu, C. Sturino, K. Metters, K. Gottesdiener, S.D. Wright, Z. Wang, E. Lai, M.G. Waters, M.G. Waters Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682 6687
6. C.F. Sturino, G. O'Neill, N. Lachance, M. Boyd, C. Berthelette, M. Labelle, L. Li, B. Roy, J. Scheigetz, N. Tsou, Y. Aubin, K.P. Bateman, N. Chauret, S.H. Day, J.F. Levesque, C. Seto, J.H. Silva, L.A. Trimble, M.C. Carriere, D. Denis, G. Greig, S. Kargman, S. Lamontagne, M.C. Mathieu, N. Sawyer, D. Slipetz, W.M. Abraham, T. Jones, M. McAuliffe, H. Piechuta, D.A. Nicoll-Griffith, Z. Wang, R. Zamboni, R.N. Young, K.M. Metters Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524) J Med Chem 50 2007 794 806
7. J.F. Paolini, Y.B. Mitchel, R. Reyes, U. Kher, E. Lai, D.J. Watson, J.M. Norquist, A.G. Meehan, H.E. Bays, M. Davidson, C.M. Ballantyne Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 2008 625 630
8. D. Maccubbin, H.E. Bays, A.G. Olsson, V. Elinoff, A. Elis, Y. Mitchel, W. Sirah, A. Betteridge, R. Reyes, Q. Yu, O. Kuznetsova, C.M. Sisk, R.C. Pasternak, J.F. Paolini Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int J Clin Pract 62 2008 1959 1970
9. J.M. Norquist, D.J. Watson, Q. Yu, J.F. Paolini, K. McQuarrie, N.C. Santanello Validation of a questionnaire to assess niacin-induced cutaneous flushing Curr Med Res Opin 23 2007 1549 1560